
Moderna, Inc.
NASDAQ•MRNA
CEO: Mr. Stephane Bancel
セクター: Healthcare
業種: Biotechnology
上場日: 2018-12-07
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
連絡先情報
時価総額
$17.16B
PER (TTM)
-6.1
19.5
配当利回り
--
52週高値
$55.20
52週安値
$22.28
52週レンジ
順位54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
9年ファンダメンタル
弱い • 2.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2017-2025
財務ダッシュボード
Q4 2025 データ
売上高
$678.00M+0.00%
直近4四半期の推移
EPS
-$2.11+0.00%
直近4四半期の推移
フリーCF
$912.00M+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Product Sales Decline Net product sales $1.17B for nine months, down 46% versus prior year, driven by lower COVID vaccine demand.
Loss Reduction Achieved Net loss $(1.996)B for nine months, representing an 18% improvement due to disciplined operating expense management.
R&D Spending Streamlined Research and development expenses $2.36B year-to-date, decreasing 31% compared to 2024 due to trial wind-downs.
Operating Cash Usage Down Net cash used in operations $(2.803)B for nine months, usage decreased 27% from prior period due to lower net loss.
リスク要因
COVID Sales Transition Anticipating full year 2025 sales decline as COVID transitions to seasonal vaccine with increased commercial competition.
Ongoing Patent Litigation Facing multiple patent infringement actions globally regarding mRNA platform technology and lipid nanoparticle components.
Manufacturing Cost Volatility Fixed nature of manufacturing costs creates variability in cost of sales percentage relative to fluctuating sales volume.
見通し
Flu Vaccine Submissions Expected Expecting to complete regulatory submissions for seasonal flu vaccine (mRNA-1010) in US, Canada, EU by January 2026.
Oncology Pipeline Progress Advancing INT in multiple Phase 3 melanoma and NSCLC trials; PA therapeutic reached registrational study enrollment.
New Manufacturing Operational International mRNA manufacturing facilities in Australia and UK became operational in Q3 2025 supporting local supply.
同業比較
売上高 (TTM)
JAZZ$4.16B
EXEL$2.32B
MRNA$1.94B
粗利益率 (最新四半期)
RNA100.0%
IONS98.5%
EXEL95.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| VRNA | $72.68B | -145.1 | -30.0% | 42.7% |
| RVMD | $19.45B | -19.8 | -49.2% | 7.0% |
| ROIV | $19.39B | -23.3 | -18.3% | 4.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
85.0%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年4月29日
EPS:-
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月6日|売上高: $1.02B-45.2%|EPS: $-0.51-1608.9%予想を上回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月1日|売上高: $142.00M-35.7%|EPS: $-2.13-36.0%予想を上回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月1日|売上高: $107.00M-35.9%|EPS: $-2.52-18.2%予想を上回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月21日|売上高: $3.20B-53.3%|EPS: $-9.27+24.9%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月7日|売上高: $1.86B+1.3%|EPS: $0.03-100.4%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月1日|売上高: $221.00M-35.8%|EPS: $-3.33-8.0%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月2日|売上高: $167.00M-90.9%|EPS: $-3.08-1640.0%予想を上回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月23日|売上高: $6.85B-63.7%|EPS: $-12.34-158.0%予想を下回る